Proactive Investors - Run By Investors For Investors

Phase II Peprostat study 'a major milestone' says Ergomed's Andrew Mackie

Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.

Meet Rainbow Rare Earths Limited, Eurasia Mining plc, Mariana Resources Ltd., Anglo Asian Mining Plc and Hannan Metals Ltd at our event, London, 09 May 2017. Register here »
View full ERGO profile

Ergomed Plc Timeline

April 13 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use